StudyID,Drug_Name,Arm_ID,Endpoint_Name,Endpoint_Type,Strategy,EP_P_value,Missing_Imput,Covariate_Adjust,MCP,Subgroup_Ana,EP_Value,EP_Unit,EP_Point,ARR,NNT,EP_95CI,Med_OS,OS_YrX,Med_PFS,ORR,pCR,Med_DOR,RMST,PRO,QoL,endpoint_group_id,endpoint_group_title_raw,endpoint_group_desc_raw,endpoint_group_title_norm,endpoint_group_desc_norm,matched_arm_id,arm_group_title_raw,arm_group_desc_raw,arm_group_title_norm,arm_group_desc_norm,match_type,title_score,desc_score,debug_notes,top_candidates_json
NCT00585195,,NCT00585195_P1,Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O1"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O2"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O3"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O4"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O5"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O6"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O7"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O8"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O9"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O10"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Maximum Tolerated Dose (MTD) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O11"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O1"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O2"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O3"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O4"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O5"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O6"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O7"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O8"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O9"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O10"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Recommended Phase 2 Dose (RP2D) of Crizotinib"", ""units"": ""milligram"", ""param"": ""Number"", ""values"": [{""group_id"": ""O11"", ""value"": ""250""}]}]",milligram,[],,,[],,,,,,,,,,O11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""274.43"", ""spread"": ""22""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""1378.05"", ""spread"": ""144""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O3"", ""value"": ""946.93"", ""spread"": ""38""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O4"", ""value"": ""1817.35"", ""spread"": ""34""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O5"", ""value"": ""2320.00""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O6"", ""value"": ""3457"", ""spread"": ""42""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O6,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O7"", ""value"": ""3078"", ""spread"": ""119""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O8"", ""value"": ""2107"", ""spread"": ""53""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O9"", ""value"": ""3979"", ""spread"": ""39""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O10"", ""value"": ""7547"", ""spread"": ""76""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_O11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O11"", ""value"": ""2489.39"", ""spread"": ""53""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O11,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O11,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""137.40"", ""spread"": ""8""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""658.64"", ""spread"": ""136""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O3"", ""value"": ""338.39"", ""spread"": ""50""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O4"", ""value"": ""558.01"", ""spread"": ""33""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O5"", ""value"": ""863.00""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O6"", ""value"": ""1731"", ""spread"": ""51""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O6,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O7"", ""value"": ""1377"", ""spread"": ""114""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O8"", ""value"": ""1300"", ""spread"": ""61""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O9"", ""value"": ""1906"", ""spread"": ""39""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O10"", ""value"": ""3423"", ""spread"": ""57""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_O11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Day -7"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O11"", ""value"": ""741.50"", ""spread"": ""45""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O11,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O11,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""457.55"", ""spread"": ""32""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""383.98"", ""spread"": ""10""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O3"", ""value"": ""763.71"", ""spread"": ""57""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_O4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O4"", ""value"": ""663.39"", ""spread"": ""56""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O4,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O4,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""206.13"", ""spread"": ""76""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""1086.99"", ""spread"": ""34""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O3"", ""value"": ""2047.13"", ""spread"": ""45""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O4"", ""value"": ""1780.21"", ""spread"": ""69""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O5"", ""value"": ""3083.93"", ""spread"": ""31""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O6"", ""value"": ""4066.67"", ""spread"": ""53""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O7"", ""value"": ""4375"", ""spread"": ""34""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O8"", ""value"": ""3385"", ""spread"": ""24""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O9"", ""value"": ""6655"", ""spread"": ""4""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O10"", ""value"": ""6362"", ""spread"": ""37""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O11"", ""value"": ""10480"", ""spread"": ""76""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_O12,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O12"", ""value"": ""3879.56"", ""spread"": ""45""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O12,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O12,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""425.90"", ""spread"": ""49""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""1595.58"", ""spread"": ""30""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O3"", ""value"": ""1719.30"", ""spread"": ""68""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O4"", ""value"": ""2255.70"", ""spread"": ""14""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O5"", ""value"": ""3054.45"", ""spread"": ""29""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O6"", ""value"": ""3644.72"", ""spread"": ""17""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O7"", ""value"": ""4815"", ""spread"": ""23""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O8"", ""value"": ""3839"", ""spread"": ""65""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O9"", ""value"": ""6330"", ""spread"": ""64""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O10"", ""value"": ""7273"", ""spread"": ""48""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O11"", ""value"": ""8733"", ""spread"": ""63""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_O12,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O12"", ""value"": ""4163.77"", ""spread"": ""40""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O12,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O12,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""7.29"", ""spread"": ""42""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""32.61"", ""spread"": ""36""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O3"", ""value"": ""48.18"", ""spread"": ""58""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O4"", ""value"": ""126.76"", ""spread"": ""97""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O5"", ""value"": ""232.59"", ""spread"": ""33""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O6"", ""value"": ""307.83"", ""spread"": ""59""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_O7,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O7"", ""value"": ""280.43"", ""spread"": ""75""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O7,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O7,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""12.68"", ""spread"": ""94""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""31.91"", ""spread"": ""34""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O3"", ""value"": ""54.04"", ""spread"": ""85""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O4"", ""value"": ""157.24"", ""spread"": ""17""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O5"", ""value"": ""232.45"", ""spread"": ""32""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O6"", ""value"": ""329.50"", ""spread"": ""40""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_O7,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Trough Concentration (Ctrough) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O7"", ""value"": ""312.99"", ""spread"": ""55""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O7,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O7,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""24.19"", ""spread"": ""36""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""67.64"", ""spread"": ""106""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O3"", ""value"": ""55.73"", ""spread"": ""45""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O4"", ""value"": ""87.02"", ""spread"": ""34""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O5"", ""value"": ""130.00""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O6"", ""value"": ""184.7"", ""spread"": ""65""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O6,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O7"", ""value"": ""115.9"", ""spread"": ""85""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O8"", ""value"": ""146.6"", ""spread"": ""31""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O9"", ""value"": ""154.3"", ""spread"": ""30""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O10"", ""value"": ""270.9"", ""spread"": ""47""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_O11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Day -7"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O11"", ""value"": ""108.40"", ""spread"": ""42""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O11,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O11,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""54.89"", ""spread"": ""53""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""64.14"", ""spread"": ""2""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O3"", ""value"": ""114.09"", ""spread"": ""48""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_O4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O4"", ""value"": ""98.86"", ""spread"": ""55""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O4,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O4,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""24.44"", ""spread"": ""68""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""85.66"", ""spread"": ""66""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O3"", ""value"": ""149.06"", ""spread"": ""29""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O4"", ""value"": ""188.84"", ""spread"": ""56""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O5"", ""value"": ""326.51"", ""spread"": ""24""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O6"", ""value"": ""420.15"", ""spread"": ""46""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O7"", ""value"": ""315.2"", ""spread"": ""50""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O8"", ""value"": ""215.5"", ""spread"": ""26""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O9"", ""value"": ""395.3"", ""spread"": ""16""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O10"", ""value"": ""379.2"", ""spread"": ""28""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O11"", ""value"": ""671.3"", ""spread"": ""76""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_O12,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O12"", ""value"": ""411.11"", ""spread"": ""51""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O12,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O12,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""47.99"", ""spread"": ""23""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""133.69"", ""spread"": ""48""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O3"", ""value"": ""146.26"", ""spread"": ""38""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O4"", ""value"": ""238.84"", ""spread"": ""12""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O5"", ""value"": ""327.94"", ""spread"": ""25""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O6"", ""value"": ""474.68"", ""spread"": ""43""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O7"", ""value"": ""275.0"", ""spread"": ""28""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O8"", ""value"": ""248.2"", ""spread"": ""60""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O9"", ""value"": ""327.9"", ""spread"": ""47""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O10"", ""value"": ""419.8"", ""spread"": ""36""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O11"", ""value"": ""700.0"", ""spread"": ""37""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_O12,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib on Cycle 2 Day 1"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O12"", ""value"": ""477.85"", ""spread"": ""44""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O12,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O12,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O1"", ""value"": ""2.00"", ""lower"": ""1.75"", ""upper"": ""4.08""}]}]",hour,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O2"", ""value"": ""4.09"", ""lower"": ""1.08"", ""upper"": ""6.00""}]}]",hour,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O3"", ""value"": ""4.00"", ""lower"": ""4.00"", ""upper"": ""4.08""}]}]",hour,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O4"", ""value"": ""4.00"", ""lower"": ""1.00"", ""upper"": ""8.95""}]}]",hour,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O5"", ""value"": ""2.02"", ""lower"": ""2.02"", ""upper"": ""2.02""}]}]",hour,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O6"", ""value"": ""4.00"", ""lower"": ""2.00"", ""upper"": ""6.00""}]}]",hour,[],,,[],,,,,,,,,,O6,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O7"", ""value"": ""2.15"", ""lower"": ""1.00"", ""upper"": ""6.00""}]}]",hour,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O8"", ""value"": ""4.00"", ""lower"": ""2.00"", ""upper"": ""8.00""}]}]",hour,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O9"", ""value"": ""4.00"", ""lower"": ""1.98"", ""upper"": ""6.00""}]}]",hour,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O10"", ""value"": ""4.99"", ""lower"": ""2.15"", ""upper"": ""6.13""}]}]",hour,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_O11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O11"", ""value"": ""4.00"", ""lower"": ""2.00"", ""upper"": ""9.33""}]}]",hour,[],,,[],,,,,,,,,,O11,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O11,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O1"", ""value"": ""2.52"", ""lower"": ""1.00"", ""upper"": ""4.02""}]}]",hour,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O2"", ""value"": ""4.00"", ""lower"": ""4.00"", ""upper"": ""4.00""}]}]",hour,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O3"", ""value"": ""4.00"", ""lower"": ""2.05"", ""upper"": ""8.02""}]}]",hour,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_O4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O4"", ""value"": ""4.05"", ""lower"": ""1.00"", ""upper"": ""9.08""}]}]",hour,[],,,[],,,,,,,,,,O4,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O4,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O1"", ""value"": ""2.00"", ""lower"": ""1.00"", ""upper"": ""4.00""}]}]",hour,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O2"", ""value"": ""2.51"", ""lower"": ""0.00"", ""upper"": ""6.08""}]}]",hour,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O3"", ""value"": ""4.07"", ""lower"": ""1.00"", ""upper"": ""6.00""}]}]",hour,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O4"", ""value"": ""5.01"", ""lower"": ""2.08"", ""upper"": ""8.03""}]}]",hour,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O5"", ""value"": ""4.00"", ""lower"": ""0.97"", ""upper"": ""6.07""}]}]",hour,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O6"", ""value"": ""4.99"", ""lower"": ""3.98"", ""upper"": ""6.22""}]}]",hour,[],,,[],,,,,,,,,,O6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O7"", ""value"": ""5.13"", ""lower"": ""1.93"", ""upper"": ""7.88""}]}]",hour,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O8"", ""value"": ""5.17"", ""lower"": ""0.933"", ""upper"": ""6.00""}]}]",hour,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O9"", ""value"": ""4.00"", ""lower"": ""4.00"", ""upper"": ""9.00""}]}]",hour,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O10"", ""value"": ""5.98"", ""lower"": ""4.00"", ""upper"": ""6.00""}]}]",hour,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O11"", ""value"": ""5.03"", ""lower"": ""4.00"", ""upper"": ""6.03""}]}]",hour,[],,,[],,,,,,,,,,O11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_O12,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib on Cycle 1 Day 15"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O12"", ""value"": ""4.00"", ""lower"": ""0.00"", ""upper"": ""9.03""}]}]",hour,[],,,[],,,,,,,,,,O12,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O12,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O1"", ""value"": ""1.02"", ""lower"": ""1.00"", ""upper"": ""4.00""}]}]",hour,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O2"", ""value"": ""3.98"", ""lower"": ""2.00"", ""upper"": ""4.02""}]}]",hour,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O3"", ""value"": ""4.00"", ""lower"": ""2.00"", ""upper"": ""4.17""}]}]",hour,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O4"", ""value"": ""4.00"", ""lower"": ""3.95"", ""upper"": ""4.00""}]}]",hour,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O5"", ""value"": ""4.00"", ""lower"": ""4.00"", ""upper"": ""6.00""}]}]",hour,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O6"", ""value"": ""4.05"", ""lower"": ""3.98"", ""upper"": ""9.00""}]}]",hour,[],,,[],,,,,,,,,,O6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O7"", ""value"": ""3.00"", ""lower"": ""1.00"", ""upper"": ""5.95""}]}]",hour,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O8"", ""value"": ""4.00"", ""lower"": ""2.08"", ""upper"": ""6.00""}]}]",hour,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O9"", ""value"": ""7.59"", ""lower"": ""6.18"", ""upper"": ""9.00""}]}]",hour,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O10"", ""value"": ""4.30"", ""lower"": ""4.00"", ""upper"": ""9.00""}]}]",hour,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O11"", ""value"": ""5.00"", ""lower"": ""4.00"", ""upper"": ""6.00""}]}]",hour,[],,,[],,,,,,,,,,O11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_O12,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Time to Reach Maximum Observed Plasma Concentration (Tmax) of Crizotinib Cycle 2 Day 1"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O12"", ""value"": ""4.00"", ""lower"": ""0.00"", ""upper"": ""9.02""}]}]",hour,[],,,[],,,,,,,,,,O12,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O12,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O1"", ""value"": ""48.20"", ""lower"": ""45.50"", ""upper"": ""56.80""}]}]",hour,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O2"", ""value"": ""46.70"", ""lower"": ""30.40"", ""upper"": ""67.20""}]}]",hour,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O3"", ""value"": ""52.60"", ""lower"": ""51.70"", ""upper"": ""53.50""}]}]",hour,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O4"", ""value"": ""47.35"", ""lower"": ""36.80"", ""upper"": ""57.70""}]}]",hour,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O5"", ""value"": ""45.70"", ""lower"": ""45.70"", ""upper"": ""45.70""}]}]",hour,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O6"", ""value"": ""43.33"", ""lower"": ""35.4"", ""upper"": ""52.3""}]}]",hour,[],,,[],,,,,,,,,,O6,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O7"", ""value"": ""49.06"", ""lower"": ""33.2"", ""upper"": ""79.3""}]}]",hour,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O8"", ""value"": ""46.36"", ""lower"": ""43.0"", ""upper"": ""49.8""}]}]",hour,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O9"", ""value"": ""42.17"", ""lower"": ""28.3"", ""upper"": ""53.8""}]}]",hour,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O10"", ""value"": ""38.78"", ""lower"": ""30.9"", ""upper"": ""55.3""}]}]",hour,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_O11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7,Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Plasma Decay Half-Life (t1/2) of Crizotinib on Day -7"", ""units"": ""hour"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O11"", ""value"": ""43.20"", ""lower"": ""27.10"", ""upper"": ""63.40""}]}]",hour,[],,,[],,,,,,,,,,O11,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O11,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O1"", ""value"": ""3""}, {""group_id"": ""O1"", ""value"": ""0""}]}]",Participants,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O2"", ""value"": ""4""}, {""group_id"": ""O2"", ""value"": ""0""}]}]",Participants,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O3"", ""value"": ""8""}, {""group_id"": ""O3"", ""value"": ""1""}]}]",Participants,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O4"", ""value"": ""7""}, {""group_id"": ""O4"", ""value"": ""2""}]}]",Participants,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O5"", ""value"": ""8""}, {""group_id"": ""O5"", ""value"": ""4""}]}]",Participants,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O6"", ""value"": ""6""}, {""group_id"": ""O6"", ""value"": ""2""}]}]",Participants,[],,,[],,,,,,,,,,O6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O7"", ""value"": ""6""}, {""group_id"": ""O7"", ""value"": ""2""}]}]",Participants,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O8"", ""value"": ""4""}, {""group_id"": ""O8"", ""value"": ""2""}]}]",Participants,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O9"", ""value"": ""3""}, {""group_id"": ""O9"", ""value"": ""1""}]}]",Participants,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O10"", ""value"": ""6""}, {""group_id"": ""O10"", ""value"": ""2""}]}]",Participants,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O11"", ""value"": ""9""}, {""group_id"": ""O11"", ""value"": ""4""}]}]",Participants,[],,,[],,,,,,,,,,O11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P12,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O12"", ""value"": ""53""}, {""group_id"": ""O12"", ""value"": ""24""}]}]",Participants,[],,,[],,,,,,,,,,O12,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days),rp2d cohort ros1 positive nsclc crizotinib 250,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,NCT00585195_P12,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,fuzzy_desc_tiebreak,97,100,fuzzy_margin_too_close,"[{""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 77, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 69, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P13,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O13"", ""value"": ""85""}, {""group_id"": ""O13"", ""value"": ""54""}]}]",Participants,[],,,[],,,,,,,,,,O13,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,NCT00585195_P13,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 74, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P14,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O14"", ""value"": ""41""}, {""group_id"": ""O14"", ""value"": ""25""}]}]",Participants,[],,,[],,,,,,,,,,O14,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,NCT00585195_P14,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P15,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O15"", ""value"": ""47""}, {""group_id"": ""O15"", ""value"": ""22""}]}]",Participants,[],,,[],,,,,,,,,,O15,"RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days).,rp2d cohort alk negative cohort 1 nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 70 cycles each cycle 21 days,NCT00585195_P15,"RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days).,rp2d cohort alk negative cohort 1 nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 70 cycles each cycle 21 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P16"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 98, ""desc_score"": 97}]"
NCT00585195,,NCT00585195_P16,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O16"", ""value"": ""18""}, {""group_id"": ""O16"", ""value"": ""9""}]}]",Participants,[],,,[],,,,,,,,,,O16,"RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).,rp2d cohort alk negative cohort 2 nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally bid with or without food for up to 70 cycles each cycle 21 days,NCT00585195_P16,"RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).,rp2d cohort alk negative cohort 2 nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally bid with or without food for up to 70 cycles each cycle 21 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P16"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 98, ""desc_score"": 97}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 77, ""desc_score"": 96}]"
NCT00585195,,NCT00585195_P17,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O17"", ""value"": ""154""}, {""group_id"": ""O17"", ""value"": ""75""}]}]",Participants,[],,,[],,,,,,,,,,O17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,NCT00585195_P17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 91, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 87, ""desc_score"": 97}]"
NCT00585195,,NCT00585195_P18,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O18"", ""value"": ""66""}, {""group_id"": ""O18"", ""value"": ""29""}]}]",Participants,[],,,[],,,,,,,,,,O18,RP2D Cohort: Enriched Other: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days).,rp2d cohort enriched other crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 54 cycles each cycle 28 days,NCT00585195_P18,RP2D Cohort: Enriched Other: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days).,rp2d cohort enriched other crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 54 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 71, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 70, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P19,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O19"", ""value"": ""18""}, {""group_id"": ""O19"", ""value"": ""7""}]}]",Participants,[],,,[],,,,,,,,,,O19,RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole,Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16.,rp2d cohort itraconazole interaction crizotinib 250 mg itraconazole,participants received with or without food crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet qd from cycle 1day1 to cycle 2 day1 thereafter 250 mg bid from cycle 2 day 2 up to 58 cycles each cycle 28 days participants also received itraconazole 200 mg qd from cycle 1 day 1 to cycle 1 day 16,NCT00585195_P19,RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole,Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16.,rp2d cohort itraconazole interaction crizotinib 250 mg itraconazole,participants received with or without food crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet qd from cycle 1day1 to cycle 2 day1 thereafter 250 mg bid from cycle 2 day 2 up to 58 cycles each cycle 28 days participants also received itraconazole 200 mg qd from cycle 1 day 1 to cycle 1 day 16,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P19"", ""arm_group_title_raw"": ""RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole"", ""arm_group_desc_raw"": ""Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 63}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 45, ""desc_score"": 63}]"
NCT00585195,,NCT00585195_P20,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O20"", ""value"": ""18""}, {""group_id"": ""O20"", ""value"": ""6""}]}]",Participants,[],,,[],,,,,,,,,,O20,RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after food.,rp2d cohort rifampin interaction crizotinib 250 mg rifampin,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food from cycle 1 day 1 up to 13 cycles each cycle 28 days participants also received commercially available rifampin 650 mg qd from cycle 1 day 16 to cycle 2 day 1 14 days either one hour before or 2 hours after food,NCT00585195_P20,RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after food.,rp2d cohort rifampin interaction crizotinib 250 mg rifampin,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food from cycle 1 day 1 up to 13 cycles each cycle 28 days participants also received commercially available rifampin 650 mg qd from cycle 1 day 16 to cycle 2 day 1 14 days either one hour before or 2 hours after food,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P20"", ""arm_group_title_raw"": ""RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after food."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 61, ""desc_score"": 68}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 71, ""desc_score"": 67}]"
NCT00585195,,NCT00585195_P21,Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation and Recommended Phase 2 Dose (RP2D) Cohort: Number of Participants With Treatment Emergent Adverse Events (TEAES) and Serious Adverse Events (SAEs)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O21"", ""value"": ""12""}, {""group_id"": ""O21"", ""value"": ""6""}]}]",Participants,[],,,[],,,,,,,,,,O21,RP2D Cohort: Midazolam Interaction: Crizotinib 250 mg +Midazolam,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID with or without food from Day 1 Cycle 1 up to 133 cycles (each cycle 28 days). Participants also received single 2 mg oral dose of Midazolam on Day -7 and another single 2-mg oral dose of Midazolam concurrently with Crizotinib on Cycle 2 Day 1,rp2d cohort midazolam interaction crizotinib 250 mg midazolam,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid with or without food from day 1 cycle 1 up to 133 cycles each cycle 28 days participants also received single 2 mg oral dose of midazolam on day 7 and another single 2 mg oral dose of midazolam concurrently with crizotinib on cycle 2 day 1,NCT00585195_P21,RP2D Cohort: Midazolam Interaction: Crizotinib 250 mg +Midazolam,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID with or without food from Day 1 Cycle 1 up to 133 cycles (each cycle 28 days). Participants also received single 2 mg oral dose of Midazolam on Day -7 and another single 2-mg oral dose of Midazolam concurrently with Crizotinib on Cycle 2 Day 1,rp2d cohort midazolam interaction crizotinib 250 mg midazolam,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid with or without food from day 1 cycle 1 up to 133 cycles each cycle 28 days participants also received single 2 mg oral dose of midazolam on day 7 and another single 2 mg oral dose of midazolam concurrently with crizotinib on cycle 2 day 1,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P21"", ""arm_group_title_raw"": ""RP2D Cohort: Midazolam Interaction: Crizotinib 250 mg +Midazolam"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID with or without food from Day 1 Cycle 1 up to 133 cycles (each cycle 28 days). Participants also received single 2 mg oral dose of Midazolam on Day -7 and another single 2-mg oral dose of Midazolam concurrently with Crizotinib on Cycle 2 Day 1"", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 60}, {""arm_id"": ""NCT00585195_P16"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 63, ""desc_score"": 60}]"
NCT00585195,,NCT00585195_P1,Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O1"", ""value"": ""0""}]}]",Participants,[],,,[],,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,NCT00585195_P1,Low Dose Escalation Cohort: Crizotinib 50 mg QD,Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 50 mg qd,participants received crizotinib 50 milligram mg capsule or tablet orally once daily qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 94, ""desc_score"": 81}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 79}]"
NCT00585195,,NCT00585195_P2,Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O2"", ""value"": ""0""}]}]",Participants,[],,,[],,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P2,Low Dose Escalation Cohort: Crizotinib 100 mg QD,"Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd,participants received crizotinib 100 mg capsule or tablet orally qd for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 100 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 89}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 49}]"
NCT00585195,,NCT00585195_P3,Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O3"", ""value"": ""1""}]}]",Participants,[],,,[],,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,NCT00585195_P3,Low Dose Escalation Cohort: Crizotinib 200 mg QD,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg qd,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally qd for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 91, ""desc_score"": 95}]"
NCT00585195,,NCT00585195_P4,Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O4"", ""value"": ""0""}]}]",Participants,[],,,[],,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,NCT00585195_P4,Low Dose Escalation Cohort: Crizotinib 200 mg BID,Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 200 mg bid,participants received crizotinib 200 mg 2 capsules tablet of 100 mg each capsule tablet orally twice daily bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 97, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P5,Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O5"", ""value"": ""0""}]}]",Participants,[],,,[],,,,,,,,,,O5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,NCT00585195_P5,Low Dose Escalation Cohort: Crizotinib 250 mg BID,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days).,low dose escalation cohort crizotinib 250 mg bid,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet bid for up to 34 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 90}]"
NCT00585195,,NCT00585195_P6,Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O6"", ""value"": ""2""}]}]",Participants,[],,,[],,,,,,,,,,O6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_P6,Low Dose Escalation Cohort: Crizotinib 300 mg BID,"Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid for up to 34 cycles each cycle 28 days and 2 mg oral dose of midazolam along with crizotinib 300 mg on cycle 2 day 1 only participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 95, ""desc_score"": 87}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 95, ""desc_score"": 58}]"
NCT00585195,,NCT00585195_P7,Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O7"", ""value"": ""0""}]}]",Participants,[],,,[],,,,,,,,,,O7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P7,High Dose Escalation Cohort: Crizotinib 300 mg QD,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 300 mg qd,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P8,Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O8"", ""value"": ""0""}]}]",Participants,[],,,[],,,,,,,,,,O8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P8,High Dose Escalation Cohort: Crizotinib 400 mg QD,Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 400 mg qd,participants received crizotinib 400 mg 4 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P9,Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O9"", ""value"": ""0""}]}]",Participants,[],,,[],,,,,,,,,,O9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P9,High Dose Escalation Cohort: Crizotinib 500 mg QD,Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 500 mg qd,participants received crizotinib 500 mg 5 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_P10,Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O10"", ""value"": ""0""}]}]",Participants,[],,,[],,,,,,,,,,O10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,NCT00585195_P10,High Dose Escalation Cohort: Crizotinib 650 mg QD,Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 650 mg qd,participants received crizotinib 650 mg 6 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 49, ""desc_score"": 92}]"
NCT00585195,,NCT00585195_P11,Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT),Primary,,[],,,,,"[{""measure_title"": ""Dose-Escalation Cohort: Number of Participants With Dose-limiting Toxicities (DLT)"", ""units"": ""Participants"", ""param"": ""Count of Participants"", ""values"": [{""group_id"": ""O11"", ""value"": ""0""}]}]",Participants,[],,,[],,,,,,,,,,O11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,NCT00585195_P11,High Dose Escalation Cohort: Crizotinib 800 mg QD,Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days).,high dose escalation cohort crizotinib 800 mg qd,participants received crizotinib 800 mg 8 capsules tablet of 100 mg each capsule tablet qd for up to 7 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P11"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 800 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 800 mg (8 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 98, ""desc_score"": 98}]"
NCT00585195,,NCT00585195_O1,Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""14.98"", ""spread"": ""19""}]}]",nanogram per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""131.72""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""239.03""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""201.56""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""96.59"", ""upper"": ""179.63""}}, {""ci"": {""pct"": ""90"", ""lower"": ""172.14"", ""upper"": ""331.93""}}, {""ci"": {""pct"": ""90"", ""lower"": ""139.33"", ""upper"": ""291.58""}}]",,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 100 mg QD (Midazolam Alone),"Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd midazolam alone,participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_O1,,,,,fallback_group_id,85,52,fallback_group_id,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 85, ""desc_score"": 52}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 83, ""desc_score"": 49}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 83, ""desc_score"": 48}]"
NCT00585195,,NCT00585195_O2,Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""19.26"", ""spread"": ""38""}]}]",nanogram per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""131.72""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""239.03""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""201.56""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""96.59"", ""upper"": ""179.63""}}, {""ci"": {""pct"": ""90"", ""lower"": ""172.14"", ""upper"": ""331.93""}}, {""ci"": {""pct"": ""90"", ""lower"": ""139.33"", ""upper"": ""291.58""}}]",,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 100 mg QD + Midazolam,Participants received Crizotinib 100 mg capsule or tablet orally QD along with single 2 mg oral dose of Midazolam on Cycle 2 Day 1.,low dose escalation cohort crizotinib 100 mg qd midazolam,participants received crizotinib 100 mg capsule or tablet orally qd along with single 2 mg oral dose of midazolam on cycle 2 day 1,NCT00585195_O2,,,,,fallback_group_id,87,67,fallback_group_id,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 87, ""desc_score"": 67}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 65}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 61}]"
NCT00585195,,NCT00585195_O3,Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O3"", ""value"": ""13.65"", ""spread"": ""10""}]}]",nanogram per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""131.72""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""239.03""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""201.56""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""96.59"", ""upper"": ""179.63""}}, {""ci"": {""pct"": ""90"", ""lower"": ""172.14"", ""upper"": ""331.93""}}, {""ci"": {""pct"": ""90"", ""lower"": ""139.33"", ""upper"": ""291.58""}}]",,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 300 mg BID (Midazolam Alone),"Participants who did not receive Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet BID on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid midazolam alone,participants who did not receive crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet bid on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_O3,,,,,fallback_group_id,77,65,fallback_group_id,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 77, ""desc_score"": 65}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 75, ""desc_score"": 64}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 75, ""desc_score"": 64}]"
NCT00585195,,NCT00585195_O4,Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O4"", ""value"": ""32.62"", ""spread"": ""40""}]}]",nanogram per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""131.72""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""239.03""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""201.56""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""96.59"", ""upper"": ""179.63""}}, {""ci"": {""pct"": ""90"", ""lower"": ""172.14"", ""upper"": ""331.93""}}, {""ci"": {""pct"": ""90"", ""lower"": ""139.33"", ""upper"": ""291.58""}}]",,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 300 mg BID + Midazolam,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID along with 2 mg oral dose of Midazolam on Cycle 2 Day 1.,low dose escalation cohort crizotinib 300 mg bid midazolam,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid along with 2 mg oral dose of midazolam on cycle 2 day 1,NCT00585195_O4,,,,,fallback_group_id,86,76,fallback_group_id,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 86, ""desc_score"": 76}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 89, ""desc_score"": 74}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 81, ""desc_score"": 74}]"
NCT00585195,,NCT00585195_O5,Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O5"", ""value"": ""12.78"", ""spread"": ""41""}]}]",nanogram per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""131.72""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""239.03""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""201.56""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""96.59"", ""upper"": ""179.63""}}, {""ci"": {""pct"": ""90"", ""lower"": ""172.14"", ""upper"": ""331.93""}}, {""ci"": {""pct"": ""90"", ""lower"": ""139.33"", ""upper"": ""291.58""}}]",,,,,,,,,,O5,RP2D Cohort: Crizotinib 250 mg (Midazolam Alone),"Participants who did not receive Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",rp2d cohort crizotinib 250 mg midazolam alone,participants who did not receive crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_O5,,,,,fallback_group_id,62,70,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 62, ""desc_score"": 70}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 58, ""desc_score"": 66}, {""arm_id"": ""NCT00585195_P16"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 57, ""desc_score"": 64}]"
NCT00585195,,NCT00585195_O6,Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Midazolam Interaction Cohort: Maximum Observed Plasma Concentration (Cmax) of Midazolam When Taken Alone or Taken With Crizotinib"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O6"", ""value"": ""25.37"", ""spread"": ""67""}]}]",nanogram per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""131.72""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""239.03""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""201.56""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""96.59"", ""upper"": ""179.63""}}, {""ci"": {""pct"": ""90"", ""lower"": ""172.14"", ""upper"": ""331.93""}}, {""ci"": {""pct"": ""90"", ""lower"": ""139.33"", ""upper"": ""291.58""}}]",,,,,,,,,,O6,RP2D Cohort: Crizotinib 250 mg + Midazolam,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) BID along with single 2 mg oral dose of Midazolam on Cycle 2 Day 1.,rp2d cohort crizotinib 250 mg midazolam,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg bid along with single 2 mg oral dose of midazolam on cycle 2 day 1,NCT00585195_O6,,,,,fallback_group_id,67,77,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 67, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 62, ""desc_score"": 74}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 64, ""desc_score"": 73}]"
NCT00585195,,NCT00585195_O1,Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""41.77"", ""spread"": ""27""}]}]",nanogram*hour per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""216.19""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""350.00""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""365.43""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""161.41"", ""upper"": ""289.56""}}, {""ci"": {""pct"": ""90"", ""lower"": ""141.09"", ""upper"": ""868.23""}}, {""ci"": {""pct"": ""90"", ""lower"": ""263.22"", ""upper"": ""507.31""}}]",,,,,,,,,,O1,Low Dose Escalation Cohort: Crizotinib 100 mg QD (Midazolam Alone),"Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 100 mg qd midazolam alone,participants who did not receive crizotinib on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_O1,,,,,fallback_group_id,85,52,fallback_group_id,"[{""arm_id"": ""NCT00585195_P2"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 100 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 100 mg capsule or tablet orally QD for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 100 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 85, ""desc_score"": 52}, {""arm_id"": ""NCT00585195_P6"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 300 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID for up to 34 cycles (each cycle 28 days) and 2 mg oral dose of Midazolam along with Crizotinib 300 mg on Cycle 2 Day 1 only. Participants who did not receive Crizotinib on Day -7, received single 2 mg oral dose of Midazolam on Day -7."", ""title_score"": 83, ""desc_score"": 49}, {""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 83, ""desc_score"": 48}]"
NCT00585195,,NCT00585195_O2,Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""90.78"", ""spread"": ""33""}]}]",nanogram*hour per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""216.19""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""350.00""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""365.43""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""161.41"", ""upper"": ""289.56""}}, {""ci"": {""pct"": ""90"", ""lower"": ""141.09"", ""upper"": ""868.23""}}, {""ci"": {""pct"": ""90"", ""lower"": ""263.22"", ""upper"": ""507.31""}}]",,,,,,,,,,O2,Low Dose Escalation Cohort: Crizotinib 100 mg QD + Midazolam,Participants received Crizotinib 100 mg capsule or tablet orally QD along with single 2 mg oral dose of Midazolam on Cycle 2 Day 1.,low dose escalation cohort crizotinib 100 mg qd midazolam,participants received crizotinib 100 mg capsule or tablet orally qd along with single 2 mg oral dose of midazolam on cycle 2 day 1,NCT00585195_O2,,,,,fallback_group_id,87,67,fallback_group_id,"[{""arm_id"": ""NCT00585195_P1"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 50 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 50 milligram (mg) capsule or tablet orally once daily (QD) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 87, ""desc_score"": 67}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 65}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 88, ""desc_score"": 61}]"
NCT00585195,,NCT00585195_O3,Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O3"", ""value"": ""37.71"", ""spread"": ""38""}]}]",nanogram*hour per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""216.19""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""350.00""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""365.43""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""161.41"", ""upper"": ""289.56""}}, {""ci"": {""pct"": ""90"", ""lower"": ""141.09"", ""upper"": ""868.23""}}, {""ci"": {""pct"": ""90"", ""lower"": ""263.22"", ""upper"": ""507.31""}}]",,,,,,,,,,O3,Low Dose Escalation Cohort: Crizotinib 300 mg BID (Midazolam Alone),"Participants who did not receive Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet BID on Day -7, received single 2 mg oral dose of Midazolam on Day -7.",low dose escalation cohort crizotinib 300 mg bid midazolam alone,participants who did not receive crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet bid on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_O3,,,,,fallback_group_id,77,65,fallback_group_id,"[{""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 77, ""desc_score"": 65}, {""arm_id"": ""NCT00585195_P8"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 400 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 400 mg (4 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 75, ""desc_score"": 64}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 75, ""desc_score"": 64}]"
NCT00585195,,NCT00585195_O4,Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O4"", ""value"": ""151.45"", ""spread"": ""31""}]}]",nanogram*hour per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""216.19""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""350.00""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""365.43""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""161.41"", ""upper"": ""289.56""}}, {""ci"": {""pct"": ""90"", ""lower"": ""141.09"", ""upper"": ""868.23""}}, {""ci"": {""pct"": ""90"", ""lower"": ""263.22"", ""upper"": ""507.31""}}]",,,,,,,,,,O4,Low Dose Escalation Cohort: Crizotinib 300 mg BID + Midazolam,Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet orally BID along with 2 mg oral dose of Midazolam on Cycle 2 Day 1.,low dose escalation cohort crizotinib 300 mg bid midazolam,participants received crizotinib 300 mg 3 capsules tablet of 100 mg each capsule tablet orally bid along with 2 mg oral dose of midazolam on cycle 2 day 1,NCT00585195_O4,,,,,fallback_group_id,86,76,fallback_group_id,"[{""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 86, ""desc_score"": 76}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 89, ""desc_score"": 74}, {""arm_id"": ""NCT00585195_P7"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 300 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 300 mg (3 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 81, ""desc_score"": 74}]"
NCT00585195,,NCT00585195_O5,Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O5"", ""value"": ""32.10"", ""spread"": ""36""}]}]",nanogram*hour per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""216.19""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""350.00""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""365.43""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""161.41"", ""upper"": ""289.56""}}, {""ci"": {""pct"": ""90"", ""lower"": ""141.09"", ""upper"": ""868.23""}}, {""ci"": {""pct"": ""90"", ""lower"": ""263.22"", ""upper"": ""507.31""}}]",,,,,,,,,,O5,RP2D Cohort: Crizotinib 250 mg (Midazolam Alone),"Participants who did not receive Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet on Day -7, received single 2 mg oral dose of Midazolam on Day -7",rp2d cohort crizotinib 250 mg midazolam alone,participants who did not receive crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet on day 7 received single 2 mg oral dose of midazolam on day 7,NCT00585195_O5,,,,,fallback_group_id,62,70,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 62, ""desc_score"": 70}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 58, ""desc_score"": 66}, {""arm_id"": ""NCT00585195_P16"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 57, ""desc_score"": 64}]"
NCT00585195,,NCT00585195_O6,Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib,Primary,,[],,,,,"[{""measure_title"": ""Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Midazolam When Taken Alone or Taken With Crizotinib"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O6"", ""value"": ""112.78"", ""spread"": ""87""}]}]",nanogram*hour per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""216.19""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""350.00""}}, {""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""365.43""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""161.41"", ""upper"": ""289.56""}}, {""ci"": {""pct"": ""90"", ""lower"": ""141.09"", ""upper"": ""868.23""}}, {""ci"": {""pct"": ""90"", ""lower"": ""263.22"", ""upper"": ""507.31""}}]",,,,,,,,,,O6,RP2D Cohort: Crizotinib 250 mg +Midazolam,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) BID along with single 2 mg oral dose of Midazolam on Cycle 2 Day 1.,rp2d cohort crizotinib 250 mg midazolam,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg bid along with single 2 mg oral dose of midazolam on cycle 2 day 1,NCT00585195_O6,,,,,fallback_group_id,67,77,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 67, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P9"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 500 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 500 mg (5 capsules/tablet of 100 mg each) capsule/tablet QD for up to 7 cycles (each cycle 28 days)."", ""title_score"": 62, ""desc_score"": 74}, {""arm_id"": ""NCT00585195_P4"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally twice daily (BID) for up to 34 cycles (each cycle 28 days)."", ""title_score"": 64, ""desc_score"": 73}]"
NCT00585195,,NCT00585195_O1,RP2D Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Crizotinib When Taken With Food,Primary,,[],,,,,"[{""measure_title"": ""RP2D Cohort: Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-24)] of Crizotinib When Taken With Food"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""1212.86"", ""spread"": ""46""}]}]",nanogram*hour per milliliter,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg With Food,Participants who were enrolled in enriched RP2D cohort received single dose of Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally with food on Day -7.,rp2d cohort crizotinib 250 mg with food,participants who were enrolled in enriched rp2d cohort received single dose of crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally with food on day 7,NCT00585195_O1,,,,,fallback_group_id,67,64,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 67, ""desc_score"": 64}, {""arm_id"": ""NCT00585195_P16"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 60, ""desc_score"": 64}, {""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 70, ""desc_score"": 62}]"
NCT00585195,,NCT00585195_O1,RP2D Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken With Food,Primary,,[],,,,,"[{""measure_title"": ""RP2D Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken With Food"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""106.24"", ""spread"": ""51""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg With Food,Participants who were enrolled in enriched RP2D cohort received single dose of Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally with food on Day -7.,rp2d cohort crizotinib 250 mg with food,participants who were enrolled in enriched rp2d cohort received single dose of crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally with food on day 7,NCT00585195_O1,,,,,fallback_group_id,67,64,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 67, ""desc_score"": 64}, {""arm_id"": ""NCT00585195_P16"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 60, ""desc_score"": 64}, {""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 70, ""desc_score"": 62}]"
NCT00585195,,NCT00585195_P17,Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib Alone and When Taken With Rifampin,Primary,,[],,,,,"[{""measure_title"": ""Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib Alone and When Taken With Rifampin"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""3110"", ""spread"": ""49""}]}]",nanogram*hour per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric mean"", ""value"": ""15.57""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""10.89"", ""upper"": ""22.26""}}]",,,,,,,,,,O1,RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg Alone,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days).,rp2d cohort rifampin interaction crizotinib 250 mg alone,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food from cycle 1 day 1 up to 13 cycles each cycle 28 days,NCT00585195_P17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,fuzzy_desc_tiebreak,63,95,fuzzy_margin_too_close,"[{""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 63, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 67, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 73, ""desc_score"": 93}]"
NCT00585195,,NCT00585195_P20,Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib Alone and When Taken With Rifampin,Primary,,[],,,,,"[{""measure_title"": ""Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib Alone and When Taken With Rifampin"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""509.6"", ""spread"": ""35""}]}]",nanogram*hour per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric mean"", ""value"": ""15.57""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""10.89"", ""upper"": ""22.26""}}]",,,,,,,,,,O2,RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg With Rifampin,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) form Cycle 1Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after a meal.,rp2d cohort rifampin interaction crizotinib 250 mg with rifampin,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid form cycle 1day 1 up to 13 cycles each cycle 28 days participants also received commercially available rifampin 650 mg qd from cycle 1 day 16 to cycle 2 day 1 14 days either one hour before or 2 hours after a meal,NCT00585195_P20,RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after food.,rp2d cohort rifampin interaction crizotinib 250 mg rifampin,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food from cycle 1 day 1 up to 13 cycles each cycle 28 days participants also received commercially available rifampin 650 mg qd from cycle 1 day 16 to cycle 2 day 1 14 days either one hour before or 2 hours after food,fuzzy_desc,96,92,,"[{""arm_id"": ""NCT00585195_P20"", ""arm_group_title_raw"": ""RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after food."", ""title_score"": 96, ""desc_score"": 92}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 46, ""desc_score"": 64}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 59, ""desc_score"": 63}]"
NCT00585195,,NCT00585195_P17,Rifampin Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib Alone and When Taken With Rifampin,Primary,,[],,,,,"[{""measure_title"": ""Rifampin Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib Alone and When Taken With Rifampin"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""326.4"", ""spread"": ""48""}]}]",nanogram per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric mean"", ""value"": ""20.64""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""14.59"", ""upper"": ""29.18""}}]",,,,,,,,,,O1,RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg Alone,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days).,rp2d cohort rifampin interaction crizotinib 250 mg alone,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food from cycle 1 day 1 up to 13 cycles each cycle 28 days,NCT00585195_P17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,fuzzy_desc_tiebreak,63,95,fuzzy_margin_too_close,"[{""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 63, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 67, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 73, ""desc_score"": 93}]"
NCT00585195,,NCT00585195_P20,Rifampin Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib Alone and When Taken With Rifampin,Primary,,[],,,,,"[{""measure_title"": ""Rifampin Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib Alone and When Taken With Rifampin"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""71.53"", ""spread"": ""49""}]}]",nanogram per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric mean"", ""value"": ""20.64""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""14.59"", ""upper"": ""29.18""}}]",,,,,,,,,,O2,RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg With Rifampin,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) form Cycle 1Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after a meal.,rp2d cohort rifampin interaction crizotinib 250 mg with rifampin,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid form cycle 1day 1 up to 13 cycles each cycle 28 days participants also received commercially available rifampin 650 mg qd from cycle 1 day 16 to cycle 2 day 1 14 days either one hour before or 2 hours after a meal,NCT00585195_P20,RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after food.,rp2d cohort rifampin interaction crizotinib 250 mg rifampin,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food from cycle 1 day 1 up to 13 cycles each cycle 28 days participants also received commercially available rifampin 650 mg qd from cycle 1 day 16 to cycle 2 day 1 14 days either one hour before or 2 hours after food,fuzzy_desc,96,92,,"[{""arm_id"": ""NCT00585195_P20"", ""arm_group_title_raw"": ""RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after food."", ""title_score"": 96, ""desc_score"": 92}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 46, ""desc_score"": 64}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 59, ""desc_score"": 63}]"
NCT00585195,,NCT00585195_P17,Rifampin Cohort: Ctrough of Crizotinib Alone and When Taken With Rifampin,Primary,,[],,,,,"[{""measure_title"": ""Rifampin Cohort: Ctrough of Crizotinib Alone and When Taken With Rifampin"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""251.7"", ""spread"": ""46""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O1,RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg Alone,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days).,rp2d cohort rifampin interaction crizotinib 250 mg alone,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food from cycle 1 day 1 up to 13 cycles each cycle 28 days,NCT00585195_P17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,fuzzy_desc_tiebreak,63,95,fuzzy_margin_too_close,"[{""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 63, ""desc_score"": 95}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 67, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 73, ""desc_score"": 93}]"
NCT00585195,,NCT00585195_P20,Rifampin Cohort: Ctrough of Crizotinib Alone and When Taken With Rifampin,Primary,,[],,,,,"[{""measure_title"": ""Rifampin Cohort: Ctrough of Crizotinib Alone and When Taken With Rifampin"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""26.67"", ""spread"": ""50""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O2,RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg With Rifampin,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) form Cycle 1Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after a meal.,rp2d cohort rifampin interaction crizotinib 250 mg with rifampin,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid form cycle 1day 1 up to 13 cycles each cycle 28 days participants also received commercially available rifampin 650 mg qd from cycle 1 day 16 to cycle 2 day 1 14 days either one hour before or 2 hours after a meal,NCT00585195_P20,RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after food.,rp2d cohort rifampin interaction crizotinib 250 mg rifampin,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food from cycle 1 day 1 up to 13 cycles each cycle 28 days participants also received commercially available rifampin 650 mg qd from cycle 1 day 16 to cycle 2 day 1 14 days either one hour before or 2 hours after food,fuzzy_desc,96,92,,"[{""arm_id"": ""NCT00585195_P20"", ""arm_group_title_raw"": ""RP2D Cohort: Rifampin Interaction: Crizotinib 250 mg +Rifampin"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food from Cycle 1 Day 1 up to 13 cycles (each cycle 28 days). Participants also received commercially available Rifampin 650 mg QD from Cycle 1 Day 16 to Cycle 2 Day 1 (14 days) either one hour before or 2 hours after food."", ""title_score"": 96, ""desc_score"": 92}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 46, ""desc_score"": 64}, {""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 59, ""desc_score"": 63}]"
NCT00585195,,NCT00585195_P19,Itraconazole Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib When Taken Alone and When Taken With Itraconazole,Primary,,[],,,,,"[{""measure_title"": ""Itraconazole Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib When Taken Alone and When Taken With Itraconazole"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""4102"", ""spread"": ""31""}]}]",nanogram*hour per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""157.40""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""136.89"", ""upper"": ""180.97""}}]",,,,,,,,,,O1,RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg Alone,Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days).,rp2d cohort itraconazole interaction crizotinib 250 mg alone,participants received with or without food crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet qd from cycle 1day1 to cycle 2 day1 thereafter 250 mg bid from cycle 2 day 2 up to 58 cycles each cycle 28 days,NCT00585195_P19,RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole,Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16.,rp2d cohort itraconazole interaction crizotinib 250 mg itraconazole,participants received with or without food crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet qd from cycle 1day1 to cycle 2 day1 thereafter 250 mg bid from cycle 2 day 2 up to 58 cycles each cycle 28 days participants also received itraconazole 200 mg qd from cycle 1 day 1 to cycle 1 day 16,fuzzy_desc,93,85,,"[{""arm_id"": ""NCT00585195_P19"", ""arm_group_title_raw"": ""RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole"", ""arm_group_desc_raw"": ""Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16."", ""title_score"": 93, ""desc_score"": 85}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 48, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 50, ""desc_score"": 76}]"
NCT00585195,,NCT00585195_P19,Itraconazole Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib When Taken Alone and When Taken With Itraconazole,Primary,,[],,,,,"[{""measure_title"": ""Itraconazole Cohort: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of Crizotinib When Taken Alone and When Taken With Itraconazole"", ""units"": ""nanogram*hour per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""6665"", ""spread"": ""16""}]}]",nanogram*hour per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""157.40""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""136.89"", ""upper"": ""180.97""}}]",,,,,,,,,,O2,Itraconazole Interaction Cohort: Crizotinib 250 mg + Itraconazole,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16. (each cycle 28 days).,itraconazole interaction cohort crizotinib 250 mg itraconazole,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet qd from cycle 1day1 to cycle 2 day1 thereafter 250 mg bid from cycle 2 day 2 up to 58 cycles each cycle 28 days participants also received itraconazole 200 mg qd from cycle 1 day 1 to cycle 1 day 16 each cycle 28 days,NCT00585195_P19,RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole,Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16.,rp2d cohort itraconazole interaction crizotinib 250 mg itraconazole,participants received with or without food crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet qd from cycle 1day1 to cycle 2 day1 thereafter 250 mg bid from cycle 2 day 2 up to 58 cycles each cycle 28 days participants also received itraconazole 200 mg qd from cycle 1 day 1 to cycle 1 day 16,fuzzy_desc,85,94,,"[{""arm_id"": ""NCT00585195_P19"", ""arm_group_title_raw"": ""RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole"", ""arm_group_desc_raw"": ""Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16."", ""title_score"": 85, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 67, ""desc_score"": 63}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 64, ""desc_score"": 63}]"
NCT00585195,,NCT00585195_P19,Itraconazole Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken Alone and When Taken With Itraconazole,Primary,,[],,,,,"[{""measure_title"": ""Itraconazole Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken Alone and When Taken With Itraconazole"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""259.9"", ""spread"": ""23""}]}]",nanogram per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""132.81""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""119.10"", ""upper"": ""148.10""}}]",,,,,,,,,,O1,RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg Alone,Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days).,rp2d cohort itraconazole interaction crizotinib 250 mg alone,participants received with or without food crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet qd from cycle 1day1 to cycle 2 day1 thereafter 250 mg bid from cycle 2 day 2 up to 58 cycles each cycle 28 days,NCT00585195_P19,RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole,Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16.,rp2d cohort itraconazole interaction crizotinib 250 mg itraconazole,participants received with or without food crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet qd from cycle 1day1 to cycle 2 day1 thereafter 250 mg bid from cycle 2 day 2 up to 58 cycles each cycle 28 days participants also received itraconazole 200 mg qd from cycle 1 day 1 to cycle 1 day 16,fuzzy_desc,93,85,,"[{""arm_id"": ""NCT00585195_P19"", ""arm_group_title_raw"": ""RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole"", ""arm_group_desc_raw"": ""Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16."", ""title_score"": 93, ""desc_score"": 85}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 48, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 50, ""desc_score"": 76}]"
NCT00585195,,NCT00585195_P19,Itraconazole Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken Alone and When Taken With Itraconazole,Primary,,[],,,,,"[{""measure_title"": ""Itraconazole Cohort: Maximum Observed Plasma Concentration (Cmax) of Crizotinib When Taken Alone and When Taken With Itraconazole"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""353.2"", ""spread"": ""14""}]}]",nanogram per milliliter,"[{""effect"": {""type"": ""Ratio of adjusted geometric means"", ""value"": ""132.81""}}]",,,"[{""ci"": {""pct"": ""90"", ""lower"": ""119.10"", ""upper"": ""148.10""}}]",,,,,,,,,,O2,RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg With Itraconazole,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16. (each cycle 28 days).,rp2d cohort itraconazole interaction crizotinib 250 mg with itraconazole,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet qd from cycle 1day1 to cycle 2 day1 thereafter 250 mg bid from cycle 2 day 2 up to 58 cycles each cycle 28 days participants also received itraconazole 200 mg qd from cycle 1 day 1 to cycle 1 day 16 each cycle 28 days,NCT00585195_P19,RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole,Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16.,rp2d cohort itraconazole interaction crizotinib 250 mg itraconazole,participants received with or without food crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet qd from cycle 1day1 to cycle 2 day1 thereafter 250 mg bid from cycle 2 day 2 up to 58 cycles each cycle 28 days participants also received itraconazole 200 mg qd from cycle 1 day 1 to cycle 1 day 16,fuzzy_desc,96,94,,"[{""arm_id"": ""NCT00585195_P19"", ""arm_group_title_raw"": ""RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole"", ""arm_group_desc_raw"": ""Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16."", ""title_score"": 96, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 63}, {""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 59, ""desc_score"": 63}]"
NCT00585195,,NCT00585195_P19,Itraconazole Cohort: Trough Plasma Concentration (Ctrough) of Crizotinib When Taken Alone and When Taken With Itraconazole,Primary,,[],,,,,"[{""measure_title"": ""Itraconazole Cohort: Trough Plasma Concentration (Ctrough) of Crizotinib When Taken Alone and When Taken With Itraconazole"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O1"", ""value"": ""136.0"", ""spread"": ""36""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O1,RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg Alone,Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days).,rp2d cohort itraconazole interaction crizotinib 250 mg alone,participants received with or without food crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet qd from cycle 1day1 to cycle 2 day1 thereafter 250 mg bid from cycle 2 day 2 up to 58 cycles each cycle 28 days,NCT00585195_P19,RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole,Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16.,rp2d cohort itraconazole interaction crizotinib 250 mg itraconazole,participants received with or without food crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet qd from cycle 1day1 to cycle 2 day1 thereafter 250 mg bid from cycle 2 day 2 up to 58 cycles each cycle 28 days participants also received itraconazole 200 mg qd from cycle 1 day 1 to cycle 1 day 16,fuzzy_desc,93,85,,"[{""arm_id"": ""NCT00585195_P19"", ""arm_group_title_raw"": ""RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole"", ""arm_group_desc_raw"": ""Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16."", ""title_score"": 93, ""desc_score"": 85}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 48, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 50, ""desc_score"": 76}]"
NCT00585195,,NCT00585195_P19,Itraconazole Cohort: Trough Plasma Concentration (Ctrough) of Crizotinib When Taken Alone and When Taken With Itraconazole,Primary,,[],,,,,"[{""measure_title"": ""Itraconazole Cohort: Trough Plasma Concentration (Ctrough) of Crizotinib When Taken Alone and When Taken With Itraconazole"", ""units"": ""nanogram per milliliter"", ""param"": ""Geometric Mean"", ""dispersion"": ""Geometric Coefficient of Variation"", ""values"": [{""group_id"": ""O2"", ""value"": ""214.0"", ""spread"": ""30""}]}]",nanogram per milliliter,[],,,[],,,,,,,,,,O2,RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg With Itraconazole,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16. (each cycle 28 days).,rp2d cohort itraconazole interaction crizotinib 250 mg with itraconazole,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet qd from cycle 1day1 to cycle 2 day1 thereafter 250 mg bid from cycle 2 day 2 up to 58 cycles each cycle 28 days participants also received itraconazole 200 mg qd from cycle 1 day 1 to cycle 1 day 16 each cycle 28 days,NCT00585195_P19,RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole,Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16.,rp2d cohort itraconazole interaction crizotinib 250 mg itraconazole,participants received with or without food crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet qd from cycle 1day1 to cycle 2 day1 thereafter 250 mg bid from cycle 2 day 2 up to 58 cycles each cycle 28 days participants also received itraconazole 200 mg qd from cycle 1 day 1 to cycle 1 day 16,fuzzy_desc,96,94,,"[{""arm_id"": ""NCT00585195_P19"", ""arm_group_title_raw"": ""RP2D Cohort: Itraconazole Interaction: Crizotinib 250 mg +Itraconazole"", ""arm_group_desc_raw"": ""Participants received with or without food Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet QD from Cycle 1Day1 to Cycle 2 Day1 thereafter 250 mg BID from Cycle 2 Day 2 up to 58 cycles (each cycle 28 days). Participants also received Itraconazole 200 mg QD from Cycle 1 Day 1 to Cycle 1 Day 16."", ""title_score"": 96, ""desc_score"": 94}, {""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 63}, {""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 59, ""desc_score"": 63}]"
NCT00585195,,NCT00585195_P12,Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR)"", ""units"": ""percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""71.7"", ""lower"": ""57.7"", ""upper"": ""83.2""}]}]",percentage of participants,[],,,[],,,,,,,,,,O1,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,NCT00585195_P12,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 73, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P13,Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR)"", ""units"": ""percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O2"", ""value"": ""32.3"", ""lower"": ""21.2"", ""upper"": ""45.1""}]}]",percentage of participants,[],,,[],,,,,,,,,,O2,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,NCT00585195_P13,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 74, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P14,Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR)"", ""units"": ""percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O3"", ""value"": ""31.6"", ""lower"": ""17.5"", ""upper"": ""48.7""}]}]",percentage of participants,[],,,[],,,,,,,,,,O3,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,NCT00585195_P14,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P16,Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR)"", ""units"": ""percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O4"", ""value"": ""19.0"", ""lower"": ""5.4"", ""upper"": ""41.9""}]}]",percentage of participants,[],,,[],,,,,,,,,,O4,"RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).,rp2d cohort alk negative cohort 2 nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally bid with or without food for up to 70 cycles each cycle 21 days,NCT00585195_P16,"RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).,rp2d cohort alk negative cohort 2 nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally bid with or without food for up to 70 cycles each cycle 21 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P16"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 98, ""desc_score"": 97}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 77, ""desc_score"": 96}]"
NCT00585195,,NCT00585195_P17,Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR)"", ""units"": ""percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O5"", ""value"": ""61.2"", ""lower"": ""51.7"", ""upper"": ""70.1""}]}]",percentage of participants,[],,,[],,,,,,,,,,O5,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,NCT00585195_P17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 91, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 87, ""desc_score"": 97}]"
NCT00585195,,NCT00585195_P18,Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Objective Response (OR)"", ""units"": ""percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O6"", ""value"": ""8.3"", ""lower"": ""0.2"", ""upper"": ""38.5""}]}]",percentage of participants,[],,,[],,,,,,,,,,O6,RP2D Cohort: Enriched Other: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days).,rp2d cohort enriched other crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 54 cycles each cycle 28 days,NCT00585195_P18,RP2D Cohort: Enriched Other: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days).,rp2d cohort enriched other crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 54 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 71, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 70, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P12,Recommended Phase 2 Dose (RP2D) Cohort: Duration of Response (DOR),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Duration of Response (DOR)"", ""units"": ""Weeks"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O1"", ""value"": ""14.5"", ""lower"": ""2.8"", ""upper"": ""45.4""}]}]",Weeks,[],,,[],,,,,,,,,,O1,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,NCT00585195_P12,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 73, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P13,Recommended Phase 2 Dose (RP2D) Cohort: Duration of Response (DOR),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Duration of Response (DOR)"", ""units"": ""Weeks"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O2"", ""value"": ""6.8"", ""lower"": ""2.8"", ""upper"": ""13.4""}]}]",Weeks,[],,,[],,,,,,,,,,O2,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,NCT00585195_P13,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 74, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P14,Recommended Phase 2 Dose (RP2D) Cohort: Duration of Response (DOR),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Duration of Response (DOR)"", ""units"": ""Weeks"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O3"", ""value"": ""5.2"", ""lower"": ""3.8"", ""upper"": ""12.2""}]}]",Weeks,[],,,[],,,,,,,,,,O3,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,NCT00585195_P14,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P17,Recommended Phase 2 Dose (RP2D) Cohort: Duration of Response (DOR),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Duration of Response (DOR)"", ""units"": ""Weeks"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O4"", ""value"": ""26.2"", ""lower"": ""8.1"", ""upper"": ""72.9""}]}]",Weeks,[],,,[],,,,,,,,,,O4,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,NCT00585195_P17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 91, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 87, ""desc_score"": 97}]"
NCT00585195,,NCT00585195_P12,Recommended Phase 2 Dose (RP2D) Cohort: Time to Response (TTR),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Time to Response (TTR)"", ""units"": ""Weeks"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O1"", ""value"": ""7.9"", ""lower"": ""4.3"", ""upper"": ""103.6""}]}]",Weeks,[],,,[],,,,,,,,,,O1,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,NCT00585195_P12,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 73, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P13,Recommended Phase 2 Dose (RP2D) Cohort: Time to Response (TTR),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Time to Response (TTR)"", ""units"": ""Weeks"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O2"", ""value"": ""7.6"", ""lower"": ""3.7"", ""upper"": ""47.3""}]}]",Weeks,[],,,[],,,,,,,,,,O2,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,NCT00585195_P13,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 74, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P14,Recommended Phase 2 Dose (RP2D) Cohort: Time to Response (TTR),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Time to Response (TTR)"", ""units"": ""Weeks"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O3"", ""value"": ""8.0"", ""lower"": ""7.1"", ""upper"": ""23.6""}]}]",Weeks,[],,,[],,,,,,,,,,O3,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,NCT00585195_P14,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P17,Recommended Phase 2 Dose (RP2D) Cohort: Time to Response (TTR),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Time to Response (TTR)"", ""units"": ""Weeks"", ""param"": ""Median"", ""dispersion"": ""Full Range"", ""values"": [{""group_id"": ""O4"", ""value"": ""7.7"", ""lower"": ""4.3"", ""upper"": ""39.6""}]}]",Weeks,[],,,[],,,,,,,,,,O4,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,NCT00585195_P17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 91, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 87, ""desc_score"": 97}]"
NCT00585195,,NCT00585195_P12,Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 8,Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 8"", ""units"": ""percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""86.8"", ""lower"": ""74.7"", ""upper"": ""94.5""}]}]",percentage of participants,[],,,[],,,,,,,,,,O1,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,NCT00585195_P12,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 73, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P13,Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 8,Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 8"", ""units"": ""percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O2"", ""value"": ""71.8"", ""lower"": ""61.0"", ""upper"": ""81.0""}]}]",percentage of participants,[],,,[],,,,,,,,,,O2,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,NCT00585195_P13,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 74, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P17,Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 8,Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 8"", ""units"": ""percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O3"", ""value"": ""79.3"", ""lower"": ""70.8"", ""upper"": ""86.3""}]}]",percentage of participants,[],,,[],,,,,,,,,,O3,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,NCT00585195_P17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 91, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 87, ""desc_score"": 97}]"
NCT00585195,,NCT00585195_P16,Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 8,Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 8"", ""units"": ""percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O4"", ""value"": ""47.6"", ""lower"": ""25.7"", ""upper"": ""70.2""}]}]",percentage of participants,[],,,[],,,,,,,,,,O4,"RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).,rp2d cohort alk negative cohort 2 nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally bid with or without food for up to 70 cycles each cycle 21 days,NCT00585195_P16,"RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).,rp2d cohort alk negative cohort 2 nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally bid with or without food for up to 70 cycles each cycle 21 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P16"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 98, ""desc_score"": 97}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 77, ""desc_score"": 96}]"
NCT00585195,,NCT00585195_P12,Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 16,Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 16"", ""units"": ""percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""79.2"", ""lower"": ""65.9"", ""upper"": ""89.2""}]}]",percentage of participants,[],,,[],,,,,,,,,,O1,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,NCT00585195_P12,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 73, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P13,Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 16,Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 16"", ""units"": ""percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O2"", ""value"": ""51.8"", ""lower"": ""40.7"", ""upper"": ""62.7""}]}]",percentage of participants,[],,,[],,,,,,,,,,O2,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,NCT00585195_P13,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 74, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P17,Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 16,Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 16"", ""units"": ""percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O3"", ""value"": ""67.2"", ""lower"": ""57.9"", ""upper"": ""75.7""}]}]",percentage of participants,[],,,[],,,,,,,,,,O3,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,NCT00585195_P17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 91, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 87, ""desc_score"": 97}]"
NCT00585195,,NCT00585195_P16,Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 16,Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Percentage of Participants With Disease Control at Week 16"", ""units"": ""percentage of participants"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O4"", ""value"": ""42.9"", ""lower"": ""21.8"", ""upper"": ""66.0""}]}]",percentage of participants,[],,,[],,,,,,,,,,O4,"RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).,rp2d cohort alk negative cohort 2 nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally bid with or without food for up to 70 cycles each cycle 21 days,NCT00585195_P16,"RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days).,rp2d cohort alk negative cohort 2 nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally bid with or without food for up to 70 cycles each cycle 21 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P16"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 2, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally BID with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 98, ""desc_score"": 97}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 77, ""desc_score"": 96}]"
NCT00585195,,NCT00585195_P12,Recommended Phase 2 Dose (RP2D) Cohort: Progression Free Survival (PFS),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Progression Free Survival (PFS)"", ""units"": ""Months"", ""param"": ""Median"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""19.3"", ""lower"": ""15.2"", ""upper"": ""39.1""}]}]",Months,[],,,[],,,,,,,,,,O1,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,NCT00585195_P12,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 73, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P13,Recommended Phase 2 Dose (RP2D) Cohort: Progression Free Survival (PFS),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Progression Free Survival (PFS)"", ""units"": ""Months"", ""param"": ""Median"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O2"", ""value"": ""7.6"", ""lower"": ""5.6"", ""upper"": ""9.1""}]}]",Months,[],,,[],,,,,,,,,,O2,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,NCT00585195_P13,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 74, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P14,Recommended Phase 2 Dose (RP2D) Cohort: Progression Free Survival (PFS),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Progression Free Survival (PFS)"", ""units"": ""Months"", ""param"": ""Median"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O3"", ""value"": ""4.0"", ""lower"": ""1.9"", ""upper"": ""6.9""}]}]",Months,[],,,[],,,,,,,,,,O3,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,NCT00585195_P14,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P17,Recommended Phase 2 Dose (RP2D) Cohort: Progression Free Survival (PFS),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Progression Free Survival (PFS)"", ""units"": ""Months"", ""param"": ""Median"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O4"", ""value"": ""10.0"", ""lower"": ""8.2"", ""upper"": ""14.7""}]}]",Months,[],,,[],,,,,,,,,,O4,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,NCT00585195_P17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 91, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 87, ""desc_score"": 97}]"
NCT00585195,,NCT00585195_P12,Recommended Phase 2 Dose (RP2D) Cohort: Probability of Being Event Free at Month 6,Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Probability of Being Event Free at Month 6"", ""units"": ""Probability of being event-free"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""76.9"", ""lower"": ""62.8"", ""upper"": ""86.1""}]}]",Probability of being event-free,[],,,[],,,,,,,,,,O1,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,NCT00585195_P12,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 73, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P13,Recommended Phase 2 Dose (RP2D) Cohort: Probability of Being Event Free at Month 6,Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Probability of Being Event Free at Month 6"", ""units"": ""Probability of being event-free"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O2"", ""value"": ""57.5"", ""lower"": ""45.3"", ""upper"": ""68.0""}]}]",Probability of being event-free,[],,,[],,,,,,,,,,O2,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,NCT00585195_P13,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 74, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P14,Recommended Phase 2 Dose (RP2D) Cohort: Probability of Being Event Free at Month 6,Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Probability of Being Event Free at Month 6"", ""units"": ""Probability of being event-free"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O3"", ""value"": ""39.0"", ""lower"": ""22.8"", ""upper"": ""54.9""}]}]",Probability of being event-free,[],,,[],,,,,,,,,,O3,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,NCT00585195_P14,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P17,Recommended Phase 2 Dose (RP2D) Cohort: Probability of Being Event Free at Month 6,Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Probability of Being Event Free at Month 6"", ""units"": ""Probability of being event-free"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O4"", ""value"": ""71.9"", ""lower"": ""61.8"", ""upper"": ""79.7""}]}]",Probability of being event-free,[],,,[],,,,,,,,,,O4,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,NCT00585195_P17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 91, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 87, ""desc_score"": 97}]"
NCT00585195,,NCT00585195_P12,Recommended Phase 2 Dose (RP2D) Cohort: Overall Survival (OS),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Overall Survival (OS)"", ""units"": ""Months"", ""param"": ""Median"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""51.4"", ""lower"": ""29.3"", ""upper"": ""NA""}]}]",Months,[],,,[],,,,,,,,,,O1,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,NCT00585195_P12,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 73, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P13,Recommended Phase 2 Dose (RP2D) Cohort: Overall Survival (OS),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Overall Survival (OS)"", ""units"": ""Months"", ""param"": ""Median"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O2"", ""value"": ""20.0"", ""lower"": ""13.2"", ""upper"": ""25.7""}]}]",Months,[],,,[],,,,,,,,,,O2,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,NCT00585195_P13,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 74, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P14,Recommended Phase 2 Dose (RP2D) Cohort: Overall Survival (OS),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Overall Survival (OS)"", ""units"": ""Months"", ""param"": ""Median"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O3"", ""value"": ""10.1"", ""lower"": ""7.1"", ""upper"": ""12.9""}]}]",Months,[],,,[],,,,,,,,,,O3,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,NCT00585195_P14,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P17,Recommended Phase 2 Dose (RP2D) Cohort: Overall Survival (OS),Primary,,[],,,,,"[{""measure_title"": ""Recommended Phase 2 Dose (RP2D) Cohort: Overall Survival (OS)"", ""units"": ""Months"", ""param"": ""Median"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O4"", ""value"": ""NA"", ""lower"": ""NA"", ""upper"": ""NA""}]}]",Months,[],,,[],,,,,,,,,,O4,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,NCT00585195_P17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 91, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 87, ""desc_score"": 97}]"
NCT00585195,,NCT00585195_P12,Probability of Participant Survival at Month 6,Primary,,[],,,,,"[{""measure_title"": ""Probability of Participant Survival at Month 6"", ""units"": ""Probability of participants survival"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""90.5"", ""lower"": ""78.7"", ""upper"": ""95.9""}]}]",Probability of participants survival,[],,,[],,,,,,,,,,O1,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,NCT00585195_P12,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 73, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P13,Probability of Participant Survival at Month 6,Primary,,[],,,,,"[{""measure_title"": ""Probability of Participant Survival at Month 6"", ""units"": ""Probability of participants survival"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O2"", ""value"": ""86.7"", ""lower"": ""77.3"", ""upper"": ""92.4""}]}]",Probability of participants survival,[],,,[],,,,,,,,,,O2,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,NCT00585195_P13,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 74, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P14,Probability of Participant Survival at Month 6,Primary,,[],,,,,"[{""measure_title"": ""Probability of Participant Survival at Month 6"", ""units"": ""Probability of participants survival"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O3"", ""value"": ""67.8"", ""lower"": ""51.1"", ""upper"": ""79.9""}]}]",Probability of participants survival,[],,,[],,,,,,,,,,O3,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,NCT00585195_P14,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P17,Probability of Participant Survival at Month 6,Primary,,[],,,,,"[{""measure_title"": ""Probability of Participant Survival at Month 6"", ""units"": ""Probability of participants survival"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O4"", ""value"": ""90.0"", ""lower"": ""82.7"", ""upper"": ""94.4""}]}]",Probability of participants survival,[],,,[],,,,,,,,,,O4,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,NCT00585195_P17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 91, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 87, ""desc_score"": 97}]"
NCT00585195,,NCT00585195_P12,Probability of Participant Survival at Month 12,Primary,,[],,,,,"[{""measure_title"": ""Probability of Participant Survival at Month 12"", ""units"": ""probability of participants survival"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""78.8"", ""lower"": ""65.0"", ""upper"": ""87.7""}]}]",probability of participants survival,[],,,[],,,,,,,,,,O1,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,NCT00585195_P12,RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days).,rp2d cohort ros1 positive nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 105 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P18"", ""arm_group_title_raw"": ""RP2D Cohort: Enriched Other: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 54 cycles (each cycle 28 days)."", ""title_score"": 73, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P13,Probability of Participant Survival at Month 12,Primary,,[],,,,,"[{""measure_title"": ""Probability of Participant Survival at Month 12"", ""units"": ""probability of participants survival"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O2"", ""value"": ""66.0"", ""lower"": ""54.0"", ""upper"": ""75.5""}]}]",probability of participants survival,[],,,[],,,,,,,,,,O2,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,NCT00585195_P13,RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days).,rp2d cohort met exon 14 alterations nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 55 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 74, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P14,Probability of Participant Survival at Month 12,Primary,,[],,,,,"[{""measure_title"": ""Probability of Participant Survival at Month 12"", ""units"": ""probability of participants survival"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O3"", ""value"": ""37.1"", ""lower"": ""22.4"", ""upper"": ""51.8""}]}]",probability of participants survival,[],,,[],,,,,,,,,,O3,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,NCT00585195_P14,RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg,Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days).,rp2d cohort met amplification nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet orally twice daily bid with or without food for up to 101 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P14"", ""arm_group_title_raw"": ""RP2D Cohort: MET Amplification NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 101 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P13"", ""arm_group_title_raw"": ""RP2D Cohort: MET Exon 14 Alterations NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 55 cycles (each cycle 28 days)."", ""title_score"": 84, ""desc_score"": 99}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 80, ""desc_score"": 99}]"
NCT00585195,,NCT00585195_P17,Probability of Participant Survival at Month 12,Primary,,[],,,,,"[{""measure_title"": ""Probability of Participant Survival at Month 12"", ""units"": ""probability of participants survival"", ""param"": ""Number"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O4"", ""value"": ""80.5"", ""lower"": ""70.9"", ""upper"": ""87.2""}]}]",probability of participants survival,[],,,[],,,,,,,,,,O4,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,NCT00585195_P17,"RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg",Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days).,rp2d cohort alk positive cohort nsclc crizotinib 250 mg,participants received crizotinib 250 mg 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg capsule tablet twice daily bid with or without food for up to 133 cycles each cycle 28 days,precise_title,100,100,,"[{""arm_id"": ""NCT00585195_P17"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Positive Cohort, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 133 cycles (each cycle 28 days)."", ""title_score"": 100, ""desc_score"": 100}, {""arm_id"": ""NCT00585195_P15"", ""arm_group_title_raw"": ""RP2D Cohort: ALK-Negative Cohort 1, NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) with or without food for up to 70 cycles (each cycle 21 days)."", ""title_score"": 91, ""desc_score"": 98}, {""arm_id"": ""NCT00585195_P12"", ""arm_group_title_raw"": ""RP2D Cohort: ROS1-Positive NSCLC: Crizotinib 250 mg"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet orally twice daily (BID) with or without food for up to 105 cycles (each cycle 28 days)."", ""title_score"": 87, ""desc_score"": 97}]"
NCT00585195,,NCT00585195_O1,"Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 1 Day 15",Primary,,[],,,,,"[{""measure_title"": ""Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 1 Day 15"", ""units"": ""Ratio"", ""param"": ""Geometric Mean"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""0.46"", ""lower"": ""0.34"", ""upper"": ""0.62""}, {""group_id"": ""O1"", ""value"": ""0.53"", ""lower"": ""0.42"", ""upper"": ""0.66""}, {""group_id"": ""O1"", ""value"": ""1.19"", ""lower"": ""0.91"", ""upper"": ""1.55""}, {""group_id"": ""O1"", ""value"": ""0.58"", ""lower"": ""0.47"", ""upper"": ""0.73""}, {""group_id"": ""O1"", ""value"": ""0.77"", ""lower"": ""0.66"", ""upper"": ""0.91""}, {""group_id"": ""O1"", ""value"": ""0.96"", ""lower"": ""0.66"", ""upper"": ""1.40""}, {""group_id"": ""O1"", ""value"": ""0.36"", ""lower"": ""0.32"", ""upper"": ""0.41""}, {""group_id"": ""O1"", ""value"": ""0.97"", ""lower"": ""0.85"", ""upper"": ""1.11""}]}]",Ratio,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O1,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_O1,"Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 2 Day 1",Primary,,[],,,,,"[{""measure_title"": ""Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 2 Day 1"", ""units"": ""Ratio"", ""param"": ""Geometric Mean"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""0.47"", ""lower"": ""0.38"", ""upper"": ""0.58""}, {""group_id"": ""O1"", ""value"": ""0.72"", ""lower"": ""0.56"", ""upper"": ""0.93""}, {""group_id"": ""O1"", ""value"": ""0.89"", ""lower"": ""0.71"", ""upper"": ""1.12""}, {""group_id"": ""O1"", ""value"": ""0.42"", ""lower"": ""0.26"", ""upper"": ""0.70""}, {""group_id"": ""O1"", ""value"": ""0.69"", ""lower"": ""0.48"", ""upper"": ""1.00""}, {""group_id"": ""O1"", ""value"": ""1.31"", ""lower"": ""0.97"", ""upper"": ""1.77""}, {""group_id"": ""O1"", ""value"": ""0.24"", ""lower"": ""0.18"", ""upper"": ""0.31""}, {""group_id"": ""O1"", ""value"": ""0.85"", ""lower"": ""0.75"", ""upper"": ""0.96""}]}]",Ratio,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O1,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_O1,"Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 4 Day 1",Primary,,[],,,,,"[{""measure_title"": ""Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 4 Day 1"", ""units"": ""Ratio"", ""param"": ""Geometric Mean"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""0.48"", ""lower"": ""0.27"", ""upper"": ""0.84""}, {""group_id"": ""O1"", ""value"": ""0.66"", ""lower"": ""0.49"", ""upper"": ""0.89""}, {""group_id"": ""O1"", ""value"": ""0.84"", ""lower"": ""0.55"", ""upper"": ""1.28""}, {""group_id"": ""O1"", ""value"": ""0.75"", ""lower"": ""0.57"", ""upper"": ""1.00""}, {""group_id"": ""O1"", ""value"": ""0.88"", ""lower"": ""0.68"", ""upper"": ""1.15""}, {""group_id"": ""O1"", ""value"": ""1.63"", ""lower"": ""0.88"", ""upper"": ""3.01""}, {""group_id"": ""O1"", ""value"": ""0.22"", ""lower"": ""0.18"", ""upper"": ""0.28""}, {""group_id"": ""O1"", ""value"": ""0.81"", ""lower"": ""0.69"", ""upper"": ""0.97""}]}]",Ratio,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O1,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_O1,"Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 6 Day 1",Primary,,[],,,,,"[{""measure_title"": ""Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 6 Day 1"", ""units"": ""Ratio"", ""param"": ""Geometric Mean"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""0.49"", ""lower"": ""0.24"", ""upper"": ""1.01""}, {""group_id"": ""O1"", ""value"": ""0.75"", ""lower"": ""0.58"", ""upper"": ""0.97""}, {""group_id"": ""O1"", ""value"": ""0.69"", ""lower"": ""0.48"", ""upper"": ""1.00""}, {""group_id"": ""O1"", ""value"": ""0.78"", ""lower"": ""0.60"", ""upper"": ""1.02""}, {""group_id"": ""O1"", ""value"": ""1.07"", ""lower"": ""0.78"", ""upper"": ""1.46""}, {""group_id"": ""O1"", ""value"": ""1.71"", ""lower"": ""1.01"", ""upper"": ""2.90""}, {""group_id"": ""O1"", ""value"": ""0.25"", ""lower"": ""0.15"", ""upper"": ""0.43""}, {""group_id"": ""O1"", ""value"": ""0.87"", ""lower"": ""0.68"", ""upper"": ""1.12""}]}]",Ratio,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O1,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_O1,"Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 9 Day 1",Primary,,[],,,,,"[{""measure_title"": ""Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 9 Day 1"", ""units"": ""Ratio"", ""param"": ""Geometric Mean"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""0.38"", ""lower"": ""0.26"", ""upper"": ""0.57""}, {""group_id"": ""O1"", ""value"": ""0.56"", ""lower"": ""0.49"", ""upper"": ""0.65""}, {""group_id"": ""O1"", ""value"": ""1.19"", ""lower"": ""0.65"", ""upper"": ""2.18""}, {""group_id"": ""O1"", ""value"": ""0.72"", ""lower"": ""0.56"", ""upper"": ""0.93""}, {""group_id"": ""O1"", ""value"": ""0.83"", ""lower"": ""0.67"", ""upper"": ""1.03""}, {""group_id"": ""O1"", ""value"": ""1.23"", ""lower"": ""1.08"", ""upper"": ""1.40""}, {""group_id"": ""O1"", ""value"": ""0.19"", ""lower"": ""0.09"", ""upper"": ""0.39""}, {""group_id"": ""O1"", ""value"": ""0.72"", ""lower"": ""0.51"", ""upper"": ""1.00""}]}]",Ratio,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O1,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_O1,"Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 12 Day 1",Primary,,[],,,,,"[{""measure_title"": ""Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 12 Day 1"", ""units"": ""Ratio"", ""param"": ""Geometric Mean"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""0.38"", ""lower"": ""0.14"", ""upper"": ""1.04""}, {""group_id"": ""O1"", ""value"": ""0.66"", ""lower"": ""0.32"", ""upper"": ""1.37""}, {""group_id"": ""O1"", ""value"": ""1.06"", ""lower"": ""0.72"", ""upper"": ""1.57""}, {""group_id"": ""O1"", ""value"": ""0.88"", ""lower"": ""0.59"", ""upper"": ""1.32""}, {""group_id"": ""O1"", ""value"": ""1.02"", ""lower"": ""0.63"", ""upper"": ""1.65""}, {""group_id"": ""O1"", ""value"": ""1.39"", ""lower"": ""0.68"", ""upper"": ""2.86""}, {""group_id"": ""O1"", ""value"": ""0.23"", ""lower"": ""0.11"", ""upper"": ""0.46""}, {""group_id"": ""O1"", ""value"": ""0.75"", ""lower"": ""0.42"", ""upper"": ""1.34""}]}]",Ratio,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O1,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_O1,"Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 15 Day 1",Primary,,[],,,,,"[{""measure_title"": ""Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 15 Day 1"", ""units"": ""Ratio"", ""param"": ""Geometric Mean"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""0.49"", ""lower"": ""0.21"", ""upper"": ""1.14""}, {""group_id"": ""O1"", ""value"": ""1.03"", ""lower"": ""0.47"", ""upper"": ""2.25""}, {""group_id"": ""O1"", ""value"": ""1.32"", ""lower"": ""0.86"", ""upper"": ""2.03""}, {""group_id"": ""O1"", ""value"": ""0.90"", ""lower"": ""0.56"", ""upper"": ""1.45""}, {""group_id"": ""O1"", ""value"": ""0.81"", ""lower"": ""0.53"", ""upper"": ""1.22""}, {""group_id"": ""O1"", ""value"": ""1.71"", ""lower"": ""0.57"", ""upper"": ""5.13""}, {""group_id"": ""O1"", ""value"": ""0.24"", ""lower"": ""0.12"", ""upper"": ""0.49""}, {""group_id"": ""O1"", ""value"": ""0.76"", ""lower"": ""0.57"", ""upper"": ""0.99""}]}]",Ratio,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O1,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_O1,"Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 18 Day 1",Primary,,[],,,,,"[{""measure_title"": ""Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 18 Day 1"", ""units"": ""Ratio"", ""param"": ""Geometric Mean"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""0.32"", ""lower"": ""0.22"", ""upper"": ""0.48""}, {""group_id"": ""O1"", ""value"": ""0.55"", ""lower"": ""0.03"", ""upper"": ""8.69""}, {""group_id"": ""O1"", ""value"": ""1.64"", ""lower"": ""1.12"", ""upper"": ""2.39""}, {""group_id"": ""O1"", ""value"": ""0.69"", ""lower"": ""0.58"", ""upper"": ""0.82""}, {""group_id"": ""O1"", ""value"": ""0.89"", ""lower"": ""0.53"", ""upper"": ""1.47""}, {""group_id"": ""O1"", ""value"": ""1.10"", ""lower"": ""0.42"", ""upper"": ""2.91""}, {""group_id"": ""O1"", ""value"": ""0.18"", ""lower"": ""0.07"", ""upper"": ""0.45""}, {""group_id"": ""O1"", ""value"": ""0.69"", ""lower"": ""0.20"", ""upper"": ""2.35""}]}]",Ratio,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O1,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_O1,"Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 21 Day 1",Primary,,[],,,,,"[{""measure_title"": ""Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 21 Day 1"", ""units"": ""Ratio"", ""param"": ""Geometric Mean"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""0.23"", ""lower"": ""0.09"", ""upper"": ""0.60""}, {""group_id"": ""O1"", ""value"": ""0.48""}, {""group_id"": ""O1"", ""value"": ""1.46"", ""lower"": ""0.62"", ""upper"": ""3.41""}, {""group_id"": ""O1"", ""value"": ""0.53"", ""lower"": ""0.12"", ""upper"": ""2.42""}, {""group_id"": ""O1"", ""value"": ""0.77"", ""lower"": ""0.44"", ""upper"": ""1.33""}, {""group_id"": ""O1"", ""value"": ""1.23"", ""lower"": ""0.00"", ""upper"": ""797.68""}, {""group_id"": ""O1"", ""value"": ""0.15"", ""lower"": ""0.00"", ""upper"": ""20.43""}, {""group_id"": ""O1"", ""value"": ""0.72"", ""lower"": ""0.09"", ""upper"": ""5.76""}]}]",Ratio,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O1,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_O1,"Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 24 Day 1",Primary,,[],,,,,"[{""measure_title"": ""Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 24 Day 1"", ""units"": ""Ratio"", ""param"": ""Geometric Mean"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""0.39"", ""lower"": ""0.00"", ""upper"": ""70772.27""}, {""group_id"": ""O1"", ""value"": ""0.70"", ""lower"": ""0.00"", ""upper"": ""11581.59""}, {""group_id"": ""O1"", ""value"": ""1.13"", ""lower"": ""0.10"", ""upper"": ""12.55""}, {""group_id"": ""O1"", ""value"": ""0.69"", ""lower"": ""0.09"", ""upper"": ""5.23""}, {""group_id"": ""O1"", ""value"": ""0.53"", ""lower"": ""0.07"", ""upper"": ""3.81""}, {""group_id"": ""O1"", ""value"": ""2.35""}, {""group_id"": ""O1"", ""value"": ""0.20"", ""lower"": ""0.00"", ""upper"": ""33217.86""}, {""group_id"": ""O1"", ""value"": ""0.90"", ""lower"": ""0.48"", ""upper"": ""1.66""}]}]",Ratio,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O1,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_O1,"Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 27 Day 1",Primary,,[],,,,,"[{""measure_title"": ""Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 27 Day 1"", ""units"": ""Ratio"", ""param"": ""Geometric Mean"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""0.46"", ""lower"": ""0.00"", ""upper"": ""61000.31""}, {""group_id"": ""O1"", ""value"": ""0.97"", ""lower"": ""0.00"", ""upper"": ""9022.66""}, {""group_id"": ""O1"", ""value"": ""1.48"", ""lower"": ""0.11"", ""upper"": ""20.69""}, {""group_id"": ""O1"", ""value"": ""0.70"", ""lower"": ""0.11"", ""upper"": ""4.50""}, {""group_id"": ""O1"", ""value"": ""0.66"", ""lower"": ""0.06"", ""upper"": ""7.53""}, {""group_id"": ""O1"", ""value"": ""1.86"", ""lower"": ""0.02"", ""upper"": ""147.95""}, {""group_id"": ""O1"", ""value"": ""0.24"", ""lower"": ""0.00"", ""upper"": ""22059.61""}, {""group_id"": ""O1"", ""value"": ""0.95"", ""lower"": ""0.24"", ""upper"": ""3.78""}]}]",Ratio,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O1,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_O1,"Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 30 Day 1",Primary,,[],,,,,"[{""measure_title"": ""Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at Cycle 30 Day 1"", ""units"": ""Ratio"", ""param"": ""Geometric Mean"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""0.16""}, {""group_id"": ""O1"", ""value"": ""0.38""}, {""group_id"": ""O1"", ""value"": ""1.14""}, {""group_id"": ""O1"", ""value"": ""0.85""}, {""group_id"": ""O1"", ""value"": ""0.80""}, {""group_id"": ""O1"", ""value"": ""1.25""}, {""group_id"": ""O1"", ""value"": ""0.09""}, {""group_id"": ""O1"", ""value"": ""0.71""}]}]",Ratio,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O1,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
NCT00585195,,NCT00585195_O1,"Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at End of Treatment",Primary,,[],,,,,"[{""measure_title"": ""Geometric Mean of Ratio of Total Testosterone, Free Testosterone, Sex Hormone Binding Globulin (SHBG), Luteinizing Hormone, Follicle Stimulating Hormone, Dihydroepiandrosterone Sulfate, Estradiol and Prolactin Levels in Males at End of Treatment"", ""units"": ""Ratio"", ""param"": ""Geometric Mean"", ""dispersion"": ""95% Confidence Interval"", ""values"": [{""group_id"": ""O1"", ""value"": ""0.40"", ""lower"": ""0.08"", ""upper"": ""2.08""}, {""group_id"": ""O1"", ""value"": ""0.66"", ""lower"": ""0.39"", ""upper"": ""1.13""}, {""group_id"": ""O1"", ""value"": ""1.48"", ""lower"": ""0.49"", ""upper"": ""4.50""}, {""group_id"": ""O1"", ""value"": ""0.52"", ""lower"": ""0.14"", ""upper"": ""1.98""}, {""group_id"": ""O1"", ""value"": ""0.85"", ""lower"": ""0.26"", ""upper"": ""2.72""}, {""group_id"": ""O1"", ""value"": ""0.62"", ""lower"": ""0.20"", ""upper"": ""1.93""}, {""group_id"": ""O1"", ""value"": ""0.64"", ""lower"": ""0.24"", ""upper"": ""1.71""}, {""group_id"": ""O1"", ""value"": ""0.41"", ""lower"": ""0.21"", ""upper"": ""0.78""}]}]",Ratio,[],,,[],,,,,,,,,,O1,RP2D Cohort: Crizotinib 250 mg,Participants received Crizotinib 250 mg tablet/capsule (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) orally BID up to 124 months.,rp2d cohort crizotinib 250 mg,participants received crizotinib 250 mg tablet capsule 2 capsules tablet of 100 mg each 1 capsule tablet of 50 mg orally bid up to 124 months,NCT00585195_O1,,,,,fallback_group_id,68,79,fallback_group_id,"[{""arm_id"": ""NCT00585195_P5"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 250 mg BID"", ""arm_group_desc_raw"": ""Participants received Crizotinib 250 mg (2 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet BID for up to 34 cycles (each cycle 28 days)."", ""title_score"": 68, ""desc_score"": 79}, {""arm_id"": ""NCT00585195_P3"", ""arm_group_title_raw"": ""Low Dose Escalation Cohort: Crizotinib 200 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 200 mg (2 capsules/tablet of 100 mg each) capsule/tablet orally QD for up to 34 cycles (each cycle 28 days)."", ""title_score"": 66, ""desc_score"": 77}, {""arm_id"": ""NCT00585195_P10"", ""arm_group_title_raw"": ""High Dose Escalation Cohort: Crizotinib 650 mg QD"", ""arm_group_desc_raw"": ""Participants received Crizotinib 650 mg (6 capsules/tablet of 100 mg each + 1 capsule/tablet of 50 mg) capsule/tablet twice daily (BID) for up to 7 cycles (each cycle 28 days)."", ""title_score"": 65, ""desc_score"": 75}]"
